The investigation proposed herein focuses on the design, synthesis, and evaluation of novel acyclic phosphonate nucleotide analogs as antiviral/anti- HIV agents for treatment of the AIDS and drug addicted AIDS patients. Specifically, the investigation seeks to exploit recent observation that a group of acyclic phosphonate nucleotides exhibited remarkable anti-HIV/antiviral activity in vitro (IC50 0.13 microM). Several design considerations indicate that it might be possible to evolve new and synthetically readily accessible acyclic nucleotide analogs as potential antiviral agents for the treatment of AIDS by (a) modifying the acyclo tail of phosphonate thymine and uracil nucleotides, (b) substituting the phenylthio or phenylselenenyl group at the C-6 position of the uracil nucleus, and (c) substituting selective halo, alkyl and aryl substituents at the C-5 position of the uracil nucleus. Adequate quantities of these compounds will be synthesized to make them available for testing against AIDS virus. The approaches to be employed in this proposal include, the development of synthetic methologies, their characterization by NMR, mass spectrum, UV, and other spectroscopic techniques. Proposed compounds will be evaluated with respect to (1) ability to inhibit the replication of HIV-1 virus, (2) toxicity, and (3) cross-sensitivity patterns to AZT- resistant strain in cell culture through collaborative arrangements with Dr. Krishna C. Agrawal at Tulane University Medical Center, New Orleans, Louisiana 70112. This local arrangement of biological testing will allow maximum efficiency in the attainment of the most effective chemical modification of acyclic unsaturated nucleotide analogs by rapidly translating the biological observations into the design of improved anti-HIV compounds.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Resource-Related Research Projects (R24)
Project #
5R24DA007970-06
Application #
6104050
Study Section
Project Start
1997-08-01
Project End
1999-07-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Xavier University of Louisiana
Department
Type
DUNS #
020857876
City
New Orleans
State
LA
Country
United States
Zip Code
70125
Mayence, Annie; Vanden Eynde, Jean Jacques; Krogstad, Fran M et al. (2004) Parallel solution-phase synthesis of conformationally restricted congeners of pentamidine and evaluation of their antiplasmodial activities. J Med Chem 47:2700-5
Mayence, Annie; Vanden Eynde, Jean Jacques; LeCour Jr, Louis et al. (2004) Piperazine-linked bisbenzamidines: a novel class of antileishmanial agents. Eur J Med Chem 39:547-53
Homayoun, P; Mandal, T; Landry, D et al. (2003) Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. J Pharm Pharmacol 55:933-8
Donkor, Isaac O; Huang, Tien L; Tao, Bin et al. (2003) Trypanocidal activity of conformationally restricted pentamidine congeners. J Med Chem 46:1041-8
Mandal, Tarun K; Bostanian, Levon A; Graves, Richard A et al. (2002) Poly(D,L-lactide-co-glycolide) encapsulated poly(vinyl alcohol) hydrogel as a drug delivery system. Pharm Res 19:1713-9
Zhang, Qiang; Ma, Peng; Iszard, Marcus et al. (2002) In vitro metabolism of R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo [1,2,3-de]1,4-benzoxazinyl]-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist. Drug Metab Dispos 30:1077-86
Brakta, Mohamed; Murthy, Devangachinta; Ellis, L'Ouverture et al. (2002) 9-[(Hydroxymethyl)phenyl]adenines: new aryladenine substrates of adenosine deaminase. Bioorg Med Chem Lett 12:1489-92
Huang, T L; Tao, B; Quarshie, Y et al. (2001) N,N'-bis[4-(N-alkylamidino)phenyl]homopiperazines as anti-Pneumocystis carinii agents. Bioorg Med Chem Lett 11:2679-81
Mandal, T K; Bostanian, L A (2000) Effect of peptide loading and surfactant concentration on the characteristics of physically crosslinked hydrogel. Pharm Dev Technol 5:555-60
Mandal, T K (2000) Swelling-controlled release system for the vaginal delivery of miconazole. Eur J Pharm Biopharm 50:337-43

Showing the most recent 10 out of 17 publications